Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative

2025-06-24 04:50:40 ET

Introduction

Hims & Hers Health ( HIMS ) entered 2025 firing on all cylinders: first-quarter revenue more than doubled to $586 million, net income surged to $49.5 million, and operating cash flow touched $109 million, giving the direct-to-consumer telehealth platform its strongest opening quarter to date. Yet, the glow lasted only eight weeks. On June 23, Novo Nordisk ( NVO ) abruptly walked away from their Wegovy distribution pact, calling Hims' parallel sale of compounded semaglutide "deceptive marketing." The headlines erased roughly one-third of Hims' market value in a single session and shifted the investment conversation from momentum to mitigation....

Read the full article on Seeking Alpha

For further details see: